Flu vaccines 48% effective so far this season, CDC says

So far this season, flu vaccines have been 48% effective in preventing medical visits, according to a CDC estimate.

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season. But, as of data ending Feb. 4, government experts don’t expect the season to come to a close right away.

CDC anticipates “several more weeks” of flu activity in parts of the U.S., according to an agency update. So far, vaccines have been 48% effective in preventing flu-related medical visits, the CDC estimates.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

That compares to 59% for last year and 19% for the year before, according to the CDC. Over 10 previous flu seasons, vaccine effectiveness has fluctuated each year, often ending up with a percentage in the 40s or 50s.

Separately this year, CDC experts recommended against any use of AstraZeneca’s FluMist on efficacy concerns from three previous seasons. AZ said it’s working to assess the situation.

All year round, experts monitor the virus and select strains for the upcoming season. But, in an effort to improve on so-so efficacy and avoid strain drift, several biopharma companies are working on “universal” vaccines that fight a range of strains over multiple years.

Sanofi, the world’s largest flu vaccine manufacturer, in late 2015 unveiled its work in the area. It announced a vax project dubbed Cobra that’s designed to protect against multiple strains by using common sequences the strains share.

Other companies and groups that have gotten into universal flu vaccine work include Johnson & Johnson’s Crucell and Scripps Research Institute, plus biotechs BiondVax and FluGen.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.